Electroconvulsive therapy (ECT) has been used for refractory psychiatric conditions in the United States since 1938. Despite this, few practitioners are comfortable recommending ECT for minors.
The primary outcomes assessed were the differences in clinically assessed depressive and manic symptoms, as well as the rate of depressive and manic episodes.
Treatment with brexpiprazole as adjunctive antidepressant therapy was safe and effective in patients with major depressive disorder.
The development of effective implementation could make virtual reality a serious, accessible therapy for individuals with specific phobias and other anxiety disorders.
Clinicians should take depression into careful consideration when treating patients with Alzheimer dementia, as the two conditions combined may predispose patients to cardiovascular disease more than either condition alone.
In both studies, the primary efficacy endpoint was change from baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.
The average MADRS-10 scores decreased from baseline, and this decrease was maintained at the end of the study.
Investigators examined the long-term efficacy of deutetrabenazine measured by Abnormal Involuntary Movement Scale, Clinical Global Impressions Scale, and Patients' Global Impression of Change Scale in real-word clinical practice settings.
Intranasal esketamine in combination with oral antidepressants demonstrated significant reduction of depressive symptoms and improved overall severity of depressive illness and health-related quality of life and functioning.
In pediatric patients with bipolar I depression, long-term treatment with lurasidone 20 mg/day is effective in reducing depressive symptoms.
Investigators pooled data from 2 phase 3 placebo-controlled studies to evaluate the safety and efficacy of lofexidine for opioid withdrawal symptoms.
Adjunctive raloxifene may reduce negative symptom scores in women with schizophrenia or schizoaffective disorder.
The phase 3 study assessed the antipsychotic efficacy and safety of ALKS 3831 in patients with acute exacerbations of schizophrenia.
In pediatric patients with ADHD, treatment with dasotraline 4 mg/day was effective in treating a range of ADHD-related symptoms and behaviors.
Younger patients treated with antipsychotics after experiencing a first episode of psychosis are at an increased risk for metabolic syndrome and cardiovascular disease.
Bupropion had a greater effect on reducing impulsivity and attention symptoms than escitalopram.
Investigators analyzed the differences in hospitalization outcomes, comorbidities, and utilization of procedures in patients with PD vs patients with PD and MDD.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Childhood-Onset Bipolar Disorder Associated With Impaired Family Functioning
- Valproate Use in Women Who Could Become Pregnant: The Argument for Informed Consent
- Hospitalization Rates in Schizophrenia—Lurasidone vs Quetiapine
- Ketamine-Induced Dissociative Symptoms Predict Antidepressant Response
- Review Examines the Effectiveness of Antidepressants for Insomnia
- Video Games and Exercise as Alternative Therapies for ADHD
- How Parents Can Enhance Autism Treatment: Use of Intervention Strategies at Home
- Electroconvulsive Therapy Effective in Children With Autism
- Comorbid Autism Spectrum Disorder and OCD: Challenges in Diagnosis and Treatment
- The Cutting Edge of Schizophrenia Research: VR as Treatment for Psychosis
- Consensus Statement: Managing Bipolar Disorder During and After Pregnancy
- Verbal Memory Linked to Temporal Lobe Thickness in First-Degree Relatives of Those With Schizophrenia
- Associations Between Maternal Depression, Support, and Cognitive Development in Offspring
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Effects of the 2 Types of Anorexia Nervosa on Bone Metabolism